BECTON DICKINSON & CO News
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.
see moreBECTON DICKINSON & CO Market News
6d
BDX Appoints New Chief Quality Officer While Advancing Tissue Regeneration Strategy
- Becton Dickinson (BDX) named Gary Sorsher as Chief Quality Officer and is accelerating its advanced tissue regeneration strategy via the PREVENT trial.
01 Aug at 02:54
BDX Stock Performance Amidst Strategic Shifts and Market Dynamics
Analyzing Becton Dickinson's recent stock movements and strategic decisions.
26 Jul at 18:40
BDX Stock Sees Institutional Interest Amid Strategic Shifts and Financial Performance
BDX stock attracts institutional investments following strategic realignments and strong financial results.
19 Jul at 18:38
BDX Stock Decline Linked to Analyst Adjustments and Market Instability
BDX stock declines due to analyst downgrades and market volatility.
12 Jul at 18:36
BDX Stock Faces Pressure Amid Analyst Downgrades and Market Volatility
BDX stock declines due to analyst downgrades and market volatility.
07 Jul at 05:24
BDX Stock Declines Amid Analyst Downgrade and Market Volatility
BDX shares fall following analyst downgrade and market shifts.
25 May at 04:09
BDX: Elyra TFL Launch and €600M Debt Deal Updates!
Becton Dickinson this week rolled out the Elyra thulium fiber laser for urology while issuing €600M of notes to refinance near-term debt. Both moves—one clinical, one capital—have clear, measurable implications for execution, revenue trajectory, and balance-sheet flexibility.